What are class two antiarrhythmic agents?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Class II Antiarrhythmic Agents

Class II antiarrhythmic agents are beta-adrenergic receptor blockers (beta-blockers), which work by blocking sympathetic stimulation of the heart. 1

Mechanism of Action

Beta-blockers exert their antiarrhythmic effects through multiple mechanisms:

  • Antisympathetic action by blocking beta-adrenergic receptors, reducing the effects of catecholamines on cardiac tissue 2
  • Suppression of automaticity in cardiac pacemaker cells, particularly those with enhanced sympathetic activity 3
  • Slowing of AV nodal conduction, which is particularly useful for rate control in supraventricular arrhythmias 1
  • Reduction of ventricular fibrillation threshold, providing protection against life-threatening arrhythmias 4
  • Prevention of catecholamine-induced arrhythmias, especially in settings of myocardial ischemia or infarction 3

Clinical Applications

Rate Control in Atrial Fibrillation

  • IV beta-blockers are drugs of choice (Class IIa, LOE A) for acute rate control in most patients with atrial fibrillation and rapid ventricular response 1
  • Beta-blockers are more effective than digoxin during exercise for rate control 1
  • The combination of digoxin and beta-blockers may be more effective than beta-blockers alone 1

Ventricular Arrhythmias

  • Beta-blockers reduce sudden death in heart failure patients (Level of Evidence A) 1
  • In polymorphic VT associated with myocardial ischemia, beta-blockers may reduce the frequency of arrhythmia recurrence (Class IIb, LOE C) 1
  • Beta-blockers have demonstrated potent antiarrhythmic effects in postinfarction trials and congestive heart failure studies 4

Pregnancy

  • Digoxin, a beta-blocker, or a nondihydropyridine calcium channel antagonist is recommended to control ventricular response in pregnant patients with AF 1
  • Metoprolol and propranolol are generally considered safe but should be avoided in the first trimester when possible 1
  • Beta-blockers should not be taken in the first trimester if possible, though they are categorized as Class C drugs (sotalol is Class B, atenolol is Class D) 1

Common Beta-Blockers Used as Antiarrhythmics

  • Propranolol - non-selective beta-blocker 5
  • Metoprolol - cardioselective beta-blocker 1
  • Atenolol - cardioselective beta-blocker 6
  • Sotalol - unique beta-blocker with additional Class III properties (potassium channel blockade) 1, 7

Important Contraindications and Precautions

Absolute Contraindications

  • Beta-blockers are contraindicated (Class III, LOE C) in patients with obstructive lung disease who develop AF 1
  • Should not be used in patients with severe bradycardia or high-degree AV block without pacemaker protection 6

Drug Interactions

  • Amiodarone combined with beta-blockers has additive negative chronotropic effects 5, 6
  • Calcium channel blockers (verapamil, diltiazem) combined with beta-blockers can cause significant bradycardia, heart failure, and cardiovascular collapse 5
  • Disopyramide with beta-blockers has been associated with severe bradycardia, asystole, and heart failure 6
  • Catecholamine-depleting drugs (reserpine) may have additive effects, causing hypotension and marked bradycardia 5, 6

Special Populations

  • Use with caution in patients with impaired hepatic or renal function 5, 6
  • Patients with peripheral arterial circulatory disorders may experience aggravation of symptoms 6
  • Patients with history of severe anaphylactic reactions may be more reactive to allergens and unresponsive to usual doses of epinephrine while on beta-blockers 5, 6

Advantages Over Other Antiarrhythmic Classes

  • Beta-blockers are generally safe agents that do not normally require therapeutic drug monitoring 2
  • Unlike Class I antiarrhythmic drugs, beta-blockers reduce mortality in patients with structural heart disease 7, 8
  • Beta-blockers reduce morbidity and may lower mortality in patients with moderate to severe heart failure 8
  • Side effects are often dose-related and can be minimized by using optimal minimal effective doses 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Therapeutic drug monitoring: antiarrhythmic drugs.

British journal of clinical pharmacology, 1998

Research

Antiarrhythmic properties of beta-blockers.

Journal of cardiovascular pharmacology, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.